Novel Therapy for Poor Responders Management
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Poor Ovarian Response
- Sponsor
- Al Baraka Fertility Hospital
- Enrollment
- 100
- Locations
- 1
- Primary Endpoint
- NUMBER OF OOCYTES
- Last Updated
- 5 years ago
Overview
Brief Summary
Unfortunately for some infertile women, gonadotrophin administration results in a desultory ovarian response. While this is commonly due to diminished ovarian reserve, as indicated by advanced age and/or elevated basal day 3 FSH concentrations, a subset of these patients are <41 years old and have normal FSH concentrations.
To overcome this problem several strategies have been reported, with limited success.
With approval of the Board, 100 women with a history of previous poor response to vigorous gonadotrophin stimulation. All with AFC ≤3, AMH;≤0.5 and they give only ≤3 oocytes in their previous cycles will be included in this study using this new protocol: clomiphene citrate 150 for 7 days starting on DAY2, associated with HMG 300 IU & Groth hormone 8 units in alternating days (i.e.; HMG on D2,4,6,8 while GH on D3,5,7,9) then folliculomonitoring will be started on D9, then Antagonist may be added till triggering then will see the response compared to their own ovarian response before
Detailed Description
Unfortunately for some infertile women, gonadotrophin administration results in a desultory ovarian response. While this is commonly due to diminished ovarian reserve, as indicated by advanced age and/or elevated basal day 3 FSH concentrations, a subset of these patients are \<41 years old and have normal FSH concentrations. To overcome this problem several strategies have been reported, with limited success. With approval of our Board, 100 women with a history of previous poor response to vigorous gonadotrophin stimulation. All with AFC ≤3, AMH;≤0.5 and they give only ≤3 oocytes in their previous cycles will be included in this study using this new protocol: clomiphene citrate 150 for 7 days starting on DAY2, associated with HMG 300 IU \& Groth hormone 8 units in alternating days (i.e.; HMG on D2,4,6,8 while GH on D3,5,7,9) then folliculomonitoring will be started on D9, then Antagonist may be added till triggering then will see the response compared to their own ovarian response before in their previous trials
Investigators
Dr. Kamal Rageh
medical director
Al Baraka Fertility Hospital
Eligibility Criteria
Inclusion Criteria
- •All with AFC ≤3,
- •and they give only ≤3 oocytes in their previous cycles
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
NUMBER OF OOCYTES
Time Frame: 2 weeks
NUMBER